文献速递消化系统肿瘤妇科肿瘤泌尿男性生殖肿瘤

MSH6致病性变异携带者的癌症风险

Cancer risks for MSH6 pathogenic variant carriers.
PubMed 文献 · Eur J Cancer · 2025-11-06

该回顾性队列研究基于360个荷兰家系、1117名MSH6致病性变异携带者(1995-2020年),采用分离分析校正确认偏倚后估算年龄和性别特异性癌症风险。结果显示男性80岁时结直肠癌累积风险36%,女性21%;子宫内膜癌女性累积风险23%;卵巢癌、泌尿道癌和胆道癌风险升高,前列腺癌和乳腺癌风险未增加。

要点

  • 男性80岁结直肠癌累积风险36%,女性21%,40岁时仍低(男0.2%、女0.9%)
  • 女性子宫内膜癌累积风险23%,卵巢癌6.4%(HR 5.58)
  • 泌尿道癌风险升高(男10.1%、女4.1%,HR 2.52),胆道癌亦升高(HR 2.76)

核心结论

  • 研究提供了MSH6致病性变异携带者年龄和性别特异性的癌症风险估计,可指导定制监测策略。

研究设计与样本

  • 回顾性队列研究,纳入360个荷兰家系、1117名1995-2020年间识别的MSH6致病性变异携带者,数据来自多个临床中心。
  • 采用分离分析计算年龄和性别特异性风险比(HR)及累积风险(CR),并校正确认偏倚。

主要发现

  • 80岁时结直肠癌累积风险男性36%(95%CI 25-48%),女性21%(95%CI 13-32%)。
  • 女性子宫内膜癌累积风险23%(95%CI 15-43%);40岁时结直肠癌风险男性0.2%、女性0.9%。
  • 卵巢癌累积风险6.4%(HR 5.58),泌尿道癌男性10.1%、女性4.1%(HR 2.52),胆道癌男性4.9%、女性4.2%(HR 2.76)。
  • 前列腺癌和乳腺癌风险未增加。

临床怎么用

  • 基于年龄和性别特异性风险估计,可支持延迟结直肠癌筛查的开始年龄。
  • 为女性提供个体化的降低风险手术咨询,尤其是子宫内膜癌和卵巢癌风险升高者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Lynch syndrome (LS) is a hereditary cancer syndrome caused by pathogenic variants (PVs) in DNA mismatch repair genes, including MSH6. Although MSH6-associated LS (MSH6-LS) is known to increase the risk of several cancers, precise risk estimates-particularly for non-colorectal cancers-remain uncertain. This limits personalised clinical guidance for MSH6-LS. This study aims to refine cancer risk estimates for individuals with pathogenic or likely pathogenic MSH6 variants. METHODS: A retrospective cohort study was conducted using data from 360 Dutch families, comprising 1117 MSH6 PV carriers identified between 1995 and 2020. Pedigree data were collected from multiple clinical centres. Cancer diagnoses were confirmed through medical records where available. Age- and sex-specific hazard ratios (HRs) and cumulative risks (CRs) were calculated using segregation analysis, adjusted for ascertainment bias. RESULTS: By age 80, the cumulative CRC risk was 36 % for males (95 % CI: 25-48 %) and 21 % for females (95 % CI: 13-32 %). For endometrial cancer, the CR was 23 % in females (95 % CI: 15-43 %). At age 40, CRC risk remained low: 0.2 % in males and 0.9 % in females. Elevated lifetime risks were observed for ovarian cancer (6.4 %; HR 5.58), urinary tract cancers (10.1 % in males, 4.1 % in females; HR 2.52), and biliary tract cancers (4.9 % in males, 4.2 % in females; HR 2.76). No increased risk was found for prostate or breast cancer. CONCLUSION: These refined, age- and sex-specific risk estimates for MSH6 PV carriers inform tailored surveillance strategies, supporting delayed CRC screening and individualised counselling on risk-reducing surgery for women.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Werf-'t Lam AV, Dowty JG, Italia M, et al. Cancer risks for MSH6 pathogenic variant carriers. Eur J Cancer. 2025. PMID: 41242000. doi:10.1016/j.ejca.2025.116098

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。